Cetera Advisor Networks’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-239
Closed -$16K 2536
2020
Q2
$16K Buy
+239
New +$14.9K ﹤0.01% 2518
2016
Q4
Sell
-6,926
Closed -$427K 973
2016
Q3
$427K Buy
6,926
+1,548
+29% +$101K 0.02% 629
2016
Q2
$341K Sell
5,378
-5,114
-49% -$322K 0.02% 580
2016
Q1
$632K Sell
10,492
-793
-7% -$48.5K 0.04% 375
2015
Q4
$788K Sell
11,285
-1,419
-11% -$101K 0.05% 329
2015
Q3
$840K Buy
12,704
+2,296
+22% +$179K 0.06% 299
2015
Q2
$792K Hold
10,408
0.05% 328
2015
Q1
$792K Sell
10,408
-2,928
-22% -$215K 0.05% 329
2014
Q4
$887K Buy
13,336
+1,656
+14% +$110K 0.06% 296
2014
Q3
$743K Buy
11,680
+545
+5% +$33.7K 0.05% 346
2014
Q2
$678K Sell
11,135
-1,881
-14% -$109K 0.04% 388
2014
Q1
$739K Buy
13,016
+2,791
+27% +$158K 0.05% 346
2013
Q4
$546K Buy
10,225
+2,817
+38% +$141K 0.04% 386
2013
Q3
$342K Buy
7,408
+1,762
+31% +$80.4K 0.03% 452
2013
Q2
$239K Buy
+5,646
New +$235K 0.02% 499

Other funds holding PJP

Cetera Advisor Networks's PJP Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Invesco Pharmaceuticals ETF (PJP) in Q3 2020, closing a stake of 239 shares — an estimated $16K sold.

Cetera Advisor Networks first reported a position in PJP in Q2 2013 and held it in 15 quarters. The position peaked at $887K in Q4 2014. 83 funds tracked by Wall St. Rank hold PJP as of Q3 2020.

  • Cetera Advisor Networks reported no remaining Invesco Pharmaceuticals ETF position as of Q3 2020 after selling out during the quarter.
  • Cetera Advisor Networks sold 239 Invesco Pharmaceuticals ETF shares in Q3 2020, an estimated $16K.
  • Cetera Advisor Networks first reported a position in Invesco Pharmaceuticals ETF in Q2 2013 and held it in 15 quarters.
  • Cetera Advisor Networks's Invesco Pharmaceuticals ETF position peaked at $887K in Q4 2014.
  • 83 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.